aSee NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for detailed recommendations, including combination regimens, in patients with no targetable genomic tumor aberrations.
bSee NCCN Guidelines® for recommendations specific to genetic alterations.
cPembrolizumab/carboplatin (or cisplatin)/pemetrexed is recommended (category 1 and preferred) as first-line therapy for certain patients with metastatic nonsquamous NSCLC.1
dPembrolizumab/carboplatin/paclitaxel (or albumin-bound paclitaxel) is recommended (category 1 and preferred) as first-line therapy for certain patients with metastatic squamous NSCLC.1
ePembrolizumab monotherapy is a category 2B recommendation in this setting.1
fPembrolizumab monotherapy is not recommended in this setting.1
Preferred intervention = Intervention that is based on superior efficacy, safety, and evidence; and, when appropriate, affordability.1
Category 1 = Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.1
Category 2B = Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.1
1L = first line, mNSCLC = metastatic NSCLC; PD-L1 = programmed death ligand 1; albumin-bound paclitaxel = paclitaxel protein-bound; NSCLC = non–small cell lung cancer.